G-Protein-Coupled Receptor Heteromers as Key Players in the Molecular Architecture of the Central Nervous System

CNS Neuroscience and Therapeutics

Volumn 20, Issue 8, 2014, Pages 703-709

  Brugarolas, Marc ^a,b,d   Navarro, Gemma ^a,b   Martínez Pinilla, Eva ^c   Angelats, Edgar ^a   Casadó, Vicent ^a,b   Lanciego, José L ^b,c   Franco, Rafael ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d EPFL   (Switzerland)

Author keywords

Adenosine receptor; Cannabinoid receptor; Dopamine receptor; Glutamate receptor; GPCR heteromer; Heteromer

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

BASAL GANGLION; BRAIN CELL; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CORPUS STRIATUM; DEGENERATIVE DISEASE; HUMAN; NEUROANATOMY; NONHUMAN; PRESYNAPTIC NERVE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; ANIMAL; CYTOLOGY; METABOLISM; NERVE CELL; PATHOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84904576722     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12277     Document Type: Review

References (76)

1. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002;1:808-820.
2. Gudermann T, Schöneberg T, Schultz G. Functional and structural complexity of signal transduction via G-protein-coupled receptors. Annu Rev Neurosci 1997;20:399-427.
3. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: Emerging paradigms. Trends Pharmacol Sci 2001;22:368-376.
4. Agnati LF, Guidolin D, Vilardaga JP, Ciruela F, Fuxe K. On the expanding terminology in the GPCR field: The meaning of receptor mosaics and receptor heteromers. J Recept Signal Transduct Res 2010;30:287-303.
5. Agnati LF, Ferré S, Lluis C, Franco R, Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 2003;55:509-550.
6. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci 2001;2:274-286.
7. Carriba P, Navarro G, Ciruela F, et al. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods 2008;5:727-733.
8. Devi LA. Heterodimerization of G-protein-coupled receptors: Pharmacology, signaling and trafficking. Trends Pharmacol Sci 2001;22:532-537.
9. Ferré S, Franco R. Oligomerization of G protein-coupled receptors: a reality. Curr Opin Pharmacol 2010;10:1-5.
10. Ferré S, Navarro G, Casadó V, et al. G protein-coupled receptor heteromers as new targets for drug development. Prog Mol Biol Transl Sci 2010;91:41-52.
11. Ferré S, Baler R, Bouvier M, et al. Building a new conceptual framework for receptor heteromers. Nat Chem Biol 2009;5:131-134.
12. Franco R, Canals M, Marcellino D, et al. Regulation of heptaspanning-membrane-receptor function by dimerization and clustering. Trends Biochem Sci 2003;28:238-243.
13. Prinster SC, Hague C, Hall RA. Heterodimerization of g protein-coupled receptors: Specificity and functional significance. Pharmacol Rev 2005;57:289-298.
14. Tadagaki K, Jockers R, Kamal M. History and biological significance of GPCR heteromerization in the neuroendocrine system. Neuroendocrinology 2012;95:223-231.
15. Breit A, Lagacé M, Bouvier M. Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem 2004;279:28756-28765.
16. Bulenger S, Marullo S, Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 2005;26:131-137.
17. Law P-Y, Erickson-Herbrandson LJ, Zha QQ, et al. Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem 2005;280:11152-11164.
18. Ferré S, Ciruela F, Woods AS, Lluis C, Franco R. Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci 2007;30:440-446.
19. Franco R, Casadó V, Cortés A, et al. Novel pharmacological targets based on receptor heteromers. Brain Res Rev 2008;58:475-482.
20. Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep 2004;5:30-34.
21. Ellis C. The State of GPCR Research in 2004. Nat Rev Drug Discov 2004;3:577-626.
22. Terrillon S, Bouvier M. Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes. EMBO J 2004;23:3950-3961.
23. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003;83:1017-1066.
24. Mackie K. Cannabinoid receptors: Where they are and what they do. J Neuroendocrinol 2008;20(Suppl 1):10-14.
25. Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F. Endocannabinoid system and mood disorders: Priming a target for new therapies. Pharmacol Ther 2013;138:18-37.
26. Brusco A, Tagliaferro P, Saez T, Onaivi ES. Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. Synapse 2008;62:944-949.
27. Gong J-P, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res 2006;1071:10-23.
28. Lanciego JL, Barroso-Chinea P, Rico AJ, et al. Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. J Psychopharmacol 2011;25:97-104.
29. Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 1998;401:163-186.
30. Hettinger BD, Lee A, Linden J, Rosin DL. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 2001;431:331-346.
31. Kreitzer AC. Physiology and pharmacology of striatal neurons. Annu Rev Neurosci 2009;32:127-147.
32. Schiffmann SN, Vanderhaeghen JJ. Does the absence of clinical expression of choreoathetosis, despite severe striatal atrophy, correlate with plasticity of neuropeptide synthesis? J Neural Transm Suppl 1991;33:99-103.
33. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 2007;83:277-292.
34. Schiffmann SN, Dassesse D, d'Alcantara P, Ledent C, Swillens S, Zoli M. A2A receptor and striatal cellular functions: Regulation of gene expression, currents, and synaptic transmission. Neurology 2003;11(Suppl 6):S24-S29.
35. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 1999;59:355-396.
36. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci 2006;7:464-476.
37. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000;97:505-519.
38. Obeso JA, Lanciego JL. Past, present, and future of the pathophysiological model of the Basal Ganglia. Front Neuroanat 2011;5:39.
39. Bonaventura J, Rico AJ, Moreno E, et al. l-DOPA-treatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus. Neuropharmacology 2013;79C:90-100.
40. Pinna A, Bonaventura J, Farré D, et al. l-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies. Exp Neurol 2014;253:180-191.
41. O'Kane EM, Stone TW. Interaction between adenosine A1 and A2 receptor-mediated responses in the rat hippocampus in vitro. Eur J Pharmacol 1998;362:17-25.
42. Ciruela F, Casadó V, Rodrigues RJ, et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 2006;26:2080-2087.
43. Cristóvão-Ferreira S, Navarro G, Brugarolas M, et al. A1R-A2AR heteromers coupled to Gs and G i/0 proteins modulate GABA transport into astrocytes. Purinergic Signal 2013;9:433-449.
44. Ferré S, Lluís C, Justinova Z, et al. Adenosine-cannabinoid receptor interactions. Implications for striatal function. Br J Pharmacol 2010;160:443-453.
45. Tebano MT, Martire A, Popoli P. Adenosine A(2A)-cannabinoid CB(1) receptor interaction: An integrative mechanism in striatal glutamatergic neurotransmission. Brain Res 2012;1476:108-118.
46. Martire A, Tebano MT, Chiodi V, et al. Pre-synaptic adenosine A2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. J Neurochem 2011;116:273-280.
47. Carriba P, Ortiz O, Patkar K, et al. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 2007;32:2249-2259.
48. Ferré S, Agnati LF, Ciruela F, et al. Neurotransmitter receptor heteromers and their integrative role in "local modules": The striatal spine module. Brain Res Rev 2007;55:55-67.
49. Ciruela F, Ferré S, Casadó V, et al. Heterodimeric adenosine receptors: A device to regulate neurotransmitter release. Cell Mol Life Sci 2006;63:2427-2431.
50. Hillion J, Canals M, Torvinen M, et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002;277:18091-18097.
51. Cabello N, Gandía J, Bertarelli DCG, et al. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem 2009;109:1497-1507.
52. Navarro G, Ferré S, Cordomi A, et al. Interactions between Intracellular Domains as Key Determinants of the Quaternary Structure and Function of Receptor Heteromers. J Biol Chem 2010;285:27346-27359.
53. Navarro G, Carriba P, Gandía J, et al. Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal 2008;8:1088-1097.
54. Fuxe K, Goldstein M, Hökfelt T, Jonsson G, Lidbrink P. Dopaminergic involvement in hypothalamic function: Extrahypothalamic and hypothalamic control. A neuroanatomical analysis. Adv Neurol 1974;5:405-419.
55. Ferre S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci U S A 1991;88:7238-7241.
56. Orru M, Bakešová J, Brugarolas M, et al. Striatal pre- and postsynaptic profile of adenosine A2A receptor antagonists. PLoS ONE 2011;6:e16088.
57. Chen W, Wang H, Wei H, Gu S, Wei H. Istradefylline, an adenosine AA receptor antagonist, for patients with Parkinson's Disease: A meta-analysis. J Neurol Sci 2013;324:21-28.
58. Park A, Stacy M. Istradefylline for the treatment of Parkinson's disease. Expert Opin Pharmacother 2012;13:111-114.
59. Ferré S, Karcz-Kubicha M, Hope BT, et al. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. Proc Natl Acad Sci U S A 2002;99:11940-11945.
60. Popoli P, Pèzzola A, Torvinen M, et al. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: Interactions with adenosine A(2a) receptors. Neuropsychopharmacology 2001;25:505-513.
61. Ossowska K, Konieczny J, Wolfarth S, Wierońska J, Pilc A. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 2001;41:413-420.
62. Kachroo A, Orlando LR, Grandy DK, Chen J-F, Young AB, Schwarzschild MA. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci 2005;25:10414-10419.
63. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997;20:482-487.
64. Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 2005;14:729-738.
65. Tebano MT, Martire A, Chiodi V, et al. Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum. J Neurochem 2009;110:1921-1930.
66. Soria G, Castañé A, Berrendero F, et al. Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. Eur J Neurosci 2004;20:2203-2213.
67. Yao L, McFarland K, Fan P, Jiang Z, Ueda T, Diamond I. Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc Natl Acad Sci U S A 2006;103:7877-7882.
68. Andersson M, Usiello A, Borgkvist A, et al. Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci 2005;25:8432-8438.
69. Hasbi A, Fan T, Alijaniaram M, et al. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci U S A 2009;106:21377-21382.
70. Perreault ML, O'Dowd BF, George SR. Dopamine receptor homooligomers and heterooligomers in schizophrenia. CNS Neurosci Ther 2011;17:52-57.
71. Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, Oflijan J, Agnati LF, Fuxe K. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes. Biochem Biophys Res Commun 2014;443:278-284.
72. Albizu L, Holloway T, González-Maeso J, Sealfon SC. Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology 2011;61:770-777.
73. Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett 2011;493:76-79.
74. Moreno JL, Muguruza C, Umali A, et al. Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function. J Biol Chem 2012;287:44301-44319.
75. González-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008;452:93-97.
76. Fribourg M, Moreno JL, Holloway T, et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 2011;147:1011-1023.